Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RGLS4326 (RG4326) is a short oligonucleotide inhibitor of microRNA-17 (miR-17), with a pioneering role in its class. This compound, with a research focus on autosomal dominant polycystic kidney disease (ADPKD), effectively suppresses the activity of miR-17 in HeLa cells, displaying an EC50 value of 28.3 nM.
产品描述 | RGLS4326 (RG4326) is a short oligonucleotide inhibitor of microRNA-17 (miR-17), with a pioneering role in its class. This compound, with a research focus on autosomal dominant polycystic kidney disease (ADPKD), effectively suppresses the activity of miR-17 in HeLa cells, displaying an EC50 value of 28.3 nM. |
体外活性 | RGLS4326, a single-stranded, chemically modified, short oligonucleotide of 9-nt with full complementarity to the miR-17 seed sequence. RGLS4326 inhibits the pathologic functions of the miR-17 family of miRNAs in ADPKD[1]. RGLS4326 treatment inhibits miR-17 function in kidney collecting duct cells in culture as measured by miR-17 PD-Sig, with an EC 50 value of 77.2?±?20.2?nM[1]. RGLS4326 suppresses the growth of primary human autosomal dominant polycystic kidney disease (ADPKD) cysts[1]. Cell Proliferation Assay[1]Cell Line: Primary cysts in 3D Matrigel Concentration: 5, 20, 100, and 300? nM Incubation Time: 9 days Result: Decreased in cyst epithelial cell proliferation. |
体内活性 | RGLS4326 preferentially distributes to kidney tubules and cysts. RGLS4326 (a single 30?mg/kg SC injection) is rapidly absorbed into plasma, showing T max of ≤1?h, C max of 8.5?μg/mL, and half-life of <4?h in wild-type mice[1]. In vivo administration of RGLS4326 also upregulates the expression of the direct miR-17 target genes Pkd1 and Pkd2[1]. Animal Model: Pkd2 -KO mice[1]Dosage: 20?mg/kg Administration: SC injection Result: Compared to non-cystic control kidneys, polycystic kidneys of PBS-treated Pkd2 -KO mice exhibit an age-dependent progressive decline in miR-17 PD-Sig, indicative of increasing miR-17 activity with disease progression. Administration of RGLS4326 reversed this decline in miR-17 PD-Sig, indicating a sustained functional inhibition of miR-17. |
别名 | RG4326, RGLS4326 |
分子量 | 3082.4 |
分子式 | C95H115F3N32O51P8S8 |
CAS No. | 2229964-07-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RGLS4326 2229964-07-0 RGLS-4326 RG4326 RG-4326 RGLS 4326 RG 4326 Inhibitor inhibitor inhibit